In a study published in the journal Immunology, Southampton University researchers have shown that a new antibody that they have engineered is able to combine two different anticancer approaches: depleting regulatory T cells and activating killer T cells [1]. Abstract The costimulatory receptor 4-1BB is expressed on activated immune cells, including activated T cells. Antibodies…

Researchers at the University of Notre Dame discovered that amino acid nitration can inhibit the activation of T cells employed in immunotherapy against cancer and that suppression of reactive nitrogen species (RNS) responsible for nitration can significantly boost the effectiveness of immunotherapy [1]. Abstract Potent immunosuppressive mechanisms within the tumor microenvironment contribute to the resistance…

Researchers at the Imperial College London have discovered that specifically employing invariant natural killer T cells, rather than generic T cells, in cancer immunotherapies based on chimeric antigen receptors might lead to significantly more effective, cheaper, and more easily mass-produced treatments [1]. Abstract Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19+ B…

Led by Dr. Alicja Copik, scientists at the University of Central Florida College of Medicine have discovered that it might be possible to make cancer immunotherapy work for a larger portion of patients by employing PM21-activated natural killer (PM21-NK) cells [1]. Study abstract Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited…

New research has identified the mechanisms responsible for enhancing immune system activity, offering new approaches for more effective cancer treatments and vaccines. Invariant natural killer T (iNKT) cells are part of the immune system’s arsenal for fighting infection and defeating diseases like cancer. Finding ways to activate these potent cells more quickly could lead to…

Researchers at Harvard have described a new cancer vaccine approach that uses an injectable biomaterial scaffold to deliver a payload of tumor-specific peptides that stimulate the immune system to respond rapidly to cancer cells. Abstract Existing strategies to enhance peptide immunogenicity for cancer vaccination generally require direct peptide alteration, which, beyond practical issues, may impact…

There may be other methods than drugs to destroy senescent cells, which accumulate with age. The immune system fails as we age, and rejuvenating it may be another route to removing harmful, pro-aging senescent cells. Senescent cells and senolytics As your body ages, increasing amounts of your cells enter into a state of senescence. Senescent…

Last year, we talked about a new cancer “vaccine” currently in clinical trials in an article here, and now a second cancer vaccine is capturing media interest due to impressive results in the lab. The new therapy is now in human clinical trials for lymphoma patients. Researchers at Stanford Medicine have found that injecting two…

Thirty-seven-year-old Nick Asoian of Denver unsuccessfully fought Hodgkin’s Lymphoma using conventional cancer treatments for two years.  In 2008, while in New Zealand for a ski race, Nick was diagnosed with the condition. Two bone marrow transplants and two years of chemotherapy combined with radiation therapy didn’t bring his cancer to heel. Nick Asoian. Image source:…

By now, the immunotherapeutic approach to fighting cancer has become so popular that you’ve most probably already heard of it—we’ve discussed it a few times too.  While immunotherapy is currently one of the best weapons in our anticancer arsenal, it is not always effective; however, researchers at Zurich University have recently found a way to…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD